CVAC Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of -5832.47% compared to CureVac NV's net margin of -227.46%. CureVac NV's return on equity of 32.68% beat BioNTech SE's return on equity of -3.91%.

CureVac NV has a consensus price target of $4.80, signalling downside risk potential of -12.37%. On the other hand BioNTech SE has an analysts' consensus of $136.00 which suggests that it could grow by 20.9%. Given that BioNTech SE has higher upside potential than CureVac NV, analysts believe BioNTech SE is more attractive than CureVac NV.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.318%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $939.6K, which are smaller than BioNTech SE quarterly revenues of $192.3M. CureVac NV's net income of -$54.8M is higher than BioNTech SE's net income of -$437.5M. Notably, CureVac NV's price-to-earnings ratio is 6.07x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 2.14x versus 9.12x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Evotec SE has a net margin of -5832.47% compared to CureVac NV's net margin of -15.79%. CureVac NV's return on equity of 32.68% beat Evotec SE's return on equity of -20.84%.

CureVac NV has a consensus price target of $4.80, signalling downside risk potential of -12.37%. On the other hand Evotec SE has an analysts' consensus of $6.1171 which suggests that it could grow by 44.98%. Given that Evotec SE has higher upside potential than CureVac NV, analysts believe Evotec SE is more attractive than CureVac NV.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Evotec SE has a beta of 1.658, suggesting its more volatile than the S&P 500 by 65.839%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $939.6K, which are smaller than Evotec SE quarterly revenues of $210.4M. CureVac NV's net income of -$54.8M is lower than Evotec SE's net income of -$33.2M. Notably, CureVac NV's price-to-earnings ratio is 6.07x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 2.14x versus 1.77x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -5832.47% compared to CureVac NV's net margin of -14092.9%. CureVac NV's return on equity of 32.68% beat InflaRx NV's return on equity of -56.78%.

CureVac NV has a consensus price target of $4.80, signalling downside risk potential of -12.37%. On the other hand InflaRx NV has an analysts' consensus of $3.62 which suggests that it could grow by 325.65%. Given that InflaRx NV has higher upside potential than CureVac NV, analysts believe InflaRx NV is more attractive than CureVac NV.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.054%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $939.6K, which are larger than InflaRx NV quarterly revenues of -$450. CureVac NV's net income of -$54.8M is lower than InflaRx NV's net income of -$8.7M. Notably, CureVac NV's price-to-earnings ratio is 6.07x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 2.14x versus 280.79x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of -5832.47% compared to CureVac NV's net margin of -214.48%. CureVac NV's return on equity of 32.68% beat Immatics NV's return on equity of -4.67%.

CureVac NV has a consensus price target of $4.80, signalling downside risk potential of -12.37%. On the other hand Immatics NV has an analysts' consensus of $14.33 which suggests that it could grow by 133.82%. Given that Immatics NV has higher upside potential than CureVac NV, analysts believe Immatics NV is more attractive than CureVac NV.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immatics NV has a beta of 0.811, suggesting its less volatile than the S&P 500 by 18.925%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $939.6K, which are smaller than Immatics NV quarterly revenues of $19.6M. CureVac NV's net income of -$54.8M is lower than Immatics NV's net income of -$41.9M. Notably, CureVac NV's price-to-earnings ratio is 6.07x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 2.14x versus 4.47x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.